Patients
We are grateful to the patients who have
chosen to participate in our previous
and ongoing clinical studies
Before a new therapy can be made available to the general public, multiple studies involving healthy volunteers and patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These may involve a new treatment (also referred to as a clinical trial) or could be an observational study. Potential new medicines need to be extensively evaluated in multiple clinical trials to understand their safety and effectiveness. In the United States, these studies are regulated by the Food and Drug Agency (FDA), and in other countries, by similar regulatory bodies.
Our Pipeline
Neumora has rapidly scaled our therapeutic pipeline through both business development activities and internal discovery capabilities. Our therapeutic pipeline is comprised of seven programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action.
Our lead program, navacaprant, is a highly selective, novel kappa opioid receptor (KOR) antagonist in Phase 3 development as a potential monotherapy treatment for MDD. Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways, which play an important role in the regulation of mood, cognition, reward, and behavior. The KOR system is a well-characterized pathway known to mediate depressive-like states, and modulating this system represents a novel approach to treating MDD and other major neuropsychiatric disorders.